Preclinical studies have suggested that VEGFR1-positive cells potentially foster the development of metastases by establishing a "premetastatic niche." We sought to test this hypothesis in highrisk localized prostate cancer and assess potential niche modulation by the VEGFR1-targeting drug axitinib. Formalin-fixed, paraffinembedded tissue derived from benign lymph nodes was collected and VEGFR1-positive cell clustering was assessed in benign lymph nodes via IHC. Recursive partitioning was used to define a threshold for VEGFR1 clustering that could segregate patients based on time to biochemical recurrence (TTBR). Multivariate analyses were used to determine whether VEGFR1 clustering, age, pathologic Tstage, Gleason score, or baseline PSA could independently predict TTBR. A randomized, phase II clinical trial comparing axitinib for 28 days followed by radical prostatectomy and pelvic lymph node dissection (RP/PLND) to RP/LND alone was then conducted, with the primary endpoint of demonstrating downregulation of VEGFR1-positve cell clustering in benign lymph nodes. Our retrospective analysis assessed a cohort of 46 patients. A threshold of 1.65 VEGFR1-positive cells per high power field was identified, below which TTBR was delayed. VEGFR1 clustering was an independent predictor of TTBR in a multivariate analysis. Only 11 out of the planned 44 patients were accrued to the phase II trial. While preoperative axitinib was safe and well tolerated, there was no sign of clinical activity or VEGFR1 downregulation. Our results validate previous findings that suggest VEGFR1-positive cells in benign lymph nodes can predict clinical outcome. Further work is needed to develop a viable clinical strategy for modulating VEGFR1 in these tissues.
Introduction
Patients with high-risk localized prostate cancer are defined by the National Comprehensive Cancer Network (NCCN) guidelines as having !T3a disease, a Gleason score of 8-10, or a baseline prostate-specific antigen (PSA) > 20 ng/mL (1). Although definitions of risk vary slightly, this is a subgroup of patients for whom definitive therapy [e.g., external beam radiotherapy (EBRT) with androgen deprivation therapy (ADT) or radical prostatectomy (RP) with pelvic lymph node dissection (PLND)] is likely indicated. Unfortunately, even with these treatment modalities, many patients develop biochemical recurrence and distant metastases (2) (3) (4) .
Recently, various genomic predictors have allowed for refinement of prognosis across all risk strata of localized prostate cancer (5, 6) . These tools harness tumor characteristics to define recurrence risk -ostensibly, features of the tumor microenvironment may also predict clinical outcome. To this end, there has been an effort to characterize the so-called "premetastatic niche" across multiple cancer types. The premetastatic niche represents a molecular milieu that fosters the growth and invasion of metastasis. In murine models of melanoma and lung cancer, Kaplan and colleagues have elegantly demonstrated that the premetastatic niche may be characterized by VEGFR1-expressing cells (7) . These cells arrive at future metastatic sites several days before the development of overt macrometastases.
The objective of the current study was first to provide validation for these preclinical observations in the context of high-risk localized prostate cancer. Given that RP for high-risk localized prostate cancer is typically accompanied by PLND, we hypothesized that VEGFR1 in benign nodal tissue could potentially predict failure of definitive therapy. A relationship between VEGFR1 in benign nodal tissue and biochemical recurrence has previously been noted in a series of Japanese patients (8) . As a second objective, we sought to determine whether abrogation of VEGFR1 signaling could delay biochemical recurrence in the same population. We therefore conducted a randomized, phase II study in patients with high-risk localized prostate cancer comparing RP/ PLND alone to RP/PLND preceded by axitinib, an oral tyrosine kinase inhibitor with affinity for VEGFR1 in the nanomolar range (9, 10) .
Materials and Methods
Retrospective assessment of VEGFR1 in benign nodal tissue Institutional review board approval (COH IRB 09213) was obtained to retrospectively obtain formalin-fixed, paraffinembedded (FFPE) tissue from a cohort of 50 patients with high-risk localized prostate cancer, defined as patients possessing any of the following preoperative criteria: (i) !T3a disease, (ii) a Gleason score of 8-10, or (iii) a baseline PSA > 20 ng/mL. Patients must have received RP/PLND at our institution with a minimum of 24 months of PSA follow-up thereafter and have had no lymph node involvement. Prospectively captured clinicopathologic information and data related to biochemical recurrence, metastatic recurrence, and overall survival for each patient in the cohort were drawn from the City of Hope Prostate Cancer Database. A total of eight 4-mm sections of benign lymph node tissue (derived from either paraffin-embedded or frozen sections) were stained with monoclonal antibodies directed at VEGFR1 (Santa Cruz Biotechnology). Using methodology similar to the cited study from Kaplan and colleagues (see Introduction), VEGFR1-expressing cell clusters were counted within eight distinct 40Â fields and the cluster count was averaged (7) . Laboratory investigators (W. Zhang and J. Deng) were blinded to clinical data. Data were unblinded to the principal investigator (S.K. Pal) and biostatistician (X. Liu) after sample assessment was complete. Time to biochemical recurrence (TTBR) was defined by the time elapsed between the date of prostatectomy and the date of a recorded PSA level ! 0.2 ng/mL. Time to metastatic progression (TTMP) was defined as the time elapsed between the date of prostatectomy and the date of radiographically documented metastasis. Overall survival (OS) was defined as the time elapsed between the date of prostatectomy and the date of death. Recursive partitioning was used to identify a cutoff for VEGFR1 clustering that optimally distinguished outcome as defined by TTBR. Multivariate analysis was conducted to understand the relationship between TTBR and the following clinicopathologic variables: (i) age, (ii) extracapsular spread, (iii) seminal vesicle invasion, (iv) Gleason grade, (v) clinical stage, (vi) baseline PSA, and (vii) VEGFR1 clustering. As data and specimens were collected retrospectively, a waiver of consent was granted.
Prospective study of preoperative axitinib: Patient selection
Prompted by our translational assessment of VEGFR1 in benign nodal tissue (see Results), we performed a randomized, phase II study of preoperative axitinib in patients with high-risk, localized prostate cancer. Eligibility for the study included a diagnosis of high-risk disease as previously defined, a commitment from the patient to undergo RP and PLND, Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, adequate hematologic and laboratory parameters, no prior systemic therapy for prostate cancer, and baseline imaging (bone scan and computerized tomography) showing no evidence of metastatic disease. As EBRT with ADT constitutes another potential option for treating highrisk localized prostate cancer, patients were required to meet with a radiation oncologist before enrollment to ensure this treatment option was sufficiently addressed. Several additional eligibility criteria were created to reflect safety considerations with axitinib, including well-controlled hypertension, no recent bleeding or thrombosis, and no significant proteinuria (!2þ). Both the protocol and informed consent were approved by the institutional scientific review committee, data safety monitoring board, and the Institutional Review Board. All enrolled patients provided written informed consent, and the study was conducted in accordance with the amended Declaration of Helsinki and the International Conference on Harmonization Guidelines.
Prospective study of preoperative axitinib: Study design
After informed consent was obtained and eligibility verified, patients were randomized to either axitinib or no systemic therapy. Patients randomized to receive axitinib were instructed to initiate therapy with 5 mg twice daily exactly 30 days before surgery, and discontinue the drug 48 hours prior the procedure. Although dose increases were not permitted, decreases of axitinib dose to 3 mg bid were permitted if treatment-related adverse events were incurred. To be considered evaluable, patients must have received 80% of the cumulative prescribed dose of axitinib over the 28-day period. Patients were seen on the day of initiation of axitinib and at the start of week two of therapy. Following surgery, patients were seen at 4 weeks, at 3 months, and every 3 months thereafter. Toxicities were graded and recorded for each patient using Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Patients had assessment of PSA at each postoperative visit. If patients were randomized to no systemic therapy, patients proceeded to RP/PLND with postoperative follow-up identical to that in the experimental arm.
Prospective study of preoperative axitinib: statistical considerations
Patients were randomized using a permuted block design. The primary endpoint of the clinical study was to determine whether axitinib led to a reduction in premetastatic niche density, defined as the number of VEGFR1-positive cell clusters in benign lymph nodes averaged over 8 distinct 40Â fields. Using a two-sample t test, a sample of 22 patients per group would result in 80% power to determine significance across groups if the average niche density was 3.13 VEGFR1 clusters per high power field (hpf) in patients in the control arm, and at most 2.19 clusters/hpf in patients treated with axitinib, with a common SD 1.43 clusters/ hpf assuming a one-sided type I error of 10%. Notably, these assumptions were informed by findings from the retrospective component of this study (see Results). Median follow-up in this cohort was 36 months.
Results

VEGRF1 in benign nodal tissue can predict time to biochemical recurrence
Viable FFPE tissue for the proposed immunohistochemical analyses was obtained from 46 patients with high-risk, localized prostate cancer. Characteristics of the cohort are shown in Table 1 . As shown, median age of the cohort was 66 and all patients were characterized as high risk on the basis of either Gleason grade (76%), baseline PSA (63%), or both (11%). No patients were characterized as high risk on the basis of perceived clinical stage. In surgical specimens, seminal vesicle invasion was found in the majority of cases (72%), but extracapsular spread was found in a smaller proportion (35%). Biochemical failure was observed in 28 patients (61%) with a median follow-up of 34 months.
With respect to staining for VEGFR1, a median of 3.13 VEGFR1-clusters/hpf was observed (range, 0-6.25). Recursive partitioning of cohorts based on VEGFR1 clustering suggested an optimal cutoff of 1.65 clusters/hpf to distinguish clinical outcome (specifically, TTBR). As shown in Fig. 1 , patients with VEGFR1 clustering below this value had a prolonged TTBR as compared with patients with VEGFR1 clustering above this threshold. On multivariate analysis including multiple clinicopathologic characteristics, as well as VEGFR1 clustering, only VEGFR1 clustering was an independent predictor of TTBR (P ¼ 0.09; see Table 2 ).
Clinical evaluation of preoperative axitinib
Between December 2011 and September 2013, a total of 11 patients were enrolled. Given the higher projected rate of accrual (approximately 2 patients per month), the study was terminated. In total, 4 patients were randomized to axitinib followed by surgery, and 7 were randomized to surgery alone. The discrepancy in patients on each study arm was on account of the permuted block design (with blocks of 4) utilized in this study. Notably, no patients refused definitive surgical intervention after the mandated consultation with a radiation oncologist. Clinicopathologic characteristics of patients enrolled on the study are noted in Table  3 . Median age of the cohort was 67 (range, 50-76). As with the previously noted correlative study, patients were principally categorized as high risk on the basis of Gleason score (81.8%), rather than baseline PSA (18.2%). All patients randomized to axitinib received 28 days of treatment; no patients required dose reduction or interruption.
With the caveat of incomplete enrollment, the study failed to meet the primary endpoint of demonstrating a reduction in VEGFR1 clustering in benign nodal tissue with use of preoperative axitinib therapy. Patients that received preoperative axitinib were found to have a median count of VEGFR1 clusters/hpf of 75.6 (range, 34.3-79.4) compared with a median of 62.5 clusters/hpf (range, 1-104.4) in patients undergoing surgery alone.
At the time of surgery, 2 patients (50%) were found to have node-positive disease in the experimental arm, and 2 patients (28.6%) were found to have node-positive disease in the control arm. A summary of pathologic findings is included in Table 3 . Patients were followed for a median of 21.4 months and, within this span of time, 1 patient (9.1%) developed PSA recurrence, with no difference amongst treatment arms (P ¼ NS). No grade 3/4 adverse events were encountered; the most frequent grade 1/2 adverse events included hypertension (27.3%), anemia (45.5%), hyperglycemia (36.4%), and hypocalcemia (36.4%).
Discussion
Our results suggest that elevated levels of VEGFR1 in benign nodal tissue collected at the time of prostatectomy predict biochemical recurrence. These findings support the preclinical observation that VEGFR1-overexpressing cells may contribute to formation of the premetastatic niche and offer validation to previous results in a similar series reported by Fujita and colleagues (8) . Presumably, abrogation of VEGFR1-mediated signaling could lead to diminution of the premetastatic niche and improve clinical outcome. We performed a randomized phase II study assessing preoperative axitinib, a potent inhibitor of VEGFR1, to test this hypothesis. Though our study suggested the safety and feasibility of axitinib in this setting, enrollment was insufficient to evaluate modulation of the premetastatic niche.
Our retrospective data differ from that of Fujita and colleagues in that our study population was enriched for patients with high-risk, localized disease, as per NCCN criteria. As such, a larger proportion of patients with Gleason 8-10 disease and baseline PSA values (>20) were included in our analysis. Furthermore, the study from Fujita and colleagues evaluated VEGFR1-positive clusters in benign lymph nodes as a dichotomous variable, whereas we explored it as a continuous variable. Despite these differences, our study can nonetheless be construed as a validation of these initial results, as both studies suggest that VEGFR1-positive clusters in benign nodal tissue can independently predict biochemical recurrence. Notably, identical antibodies and conditions were used to assess VEGFR1 across these two experiences.
The prognostic role of VEGFR1 has been previously explored directly in tumor tissues. Talagas and colleagues assessed a series of 45 patients with distant relapse of prostate cancer following prostatectomy, and 68 patients without distant relapse (11) . VEGFR1, VEGFR2, and neuropilin-1 (NRP1) in tumor endothelial cells was a strong predictor of metastatic recurrence. One perceived weakness of our retrospective study and that of Fujita and colleagues is that the primary tumor was not assessed for VEGFR1-positive cell clusters-only the associated benign nodal tissue. However, Woollard and colleagues reported a detailed assessment of 52 primary prostate cancer specimens and reported relatively weak expression of VEGFR1 in benign stroma as compared with primary prostatic tissues (12) . Thus, the approach of assessing benign tissue may yield a higher and more reliable signal for VEGFR1 positivity.
The randomized, phase II study reported herein provided an excellent opportunity to translate the findings of our retrospective experience into a potential therapeutic strategy. To be clear, the primary intent of our study (with a projected sample size of 44 patients) was to determine whether axitinib could modulate levels of VEGFR1 in benign nodal tissue. A much larger study, likely including several hundred patients, would be necessary to determine a meaningful benefit in clinical outcome (e.g., biochemical or metastatic recurrence). Although our study did not achieve its primary endpoint, it did demonstrate the safety and viability of a VEGF-directed therapy in the neoadjuvant setting. Given the lack of any observed down-staging or down-grading of disease, there is no strong impetus to move forward with further assessment of neoadjuvant monotherapy with axitinib, especially with more encouraging data using novel endocrine therapies in a similar fashion. For instance, complete and near complete pathologic responses have been observed in a neoadjuvant assessment of enzalutamide in high-risk localized prostate cancer-certainly these agents may be more appropriate for further study (13) . VEGF-directed therapies have been rigorously assessed in the setting of metastatic castration-resistant prostate cancer (mCRPC). Phase III studies evaluating sunitinib and bevacizumab showed some evidence of activity, but failed to achieve their primary endpoint (14, 15) . In our opinion, the lack of activity of VEGF-directed therapies in the setting of advanced prostate cancer, which was disclosed in the informed consent process, did lead to diminished enthusiasm for the study and greatly impeded accrual.
In summary, our retrospective study provides validation for the role of VEGFR1 clusters in benign lymph nodes as an independent prognostic marker in localized prostate cancer. Given limited accrual to the randomized, phase II clinical trial reported herein, we are limited in our conclusions and can only suggest that axitinib is safe and well-tolerated in the neoadjuvant setting, consistent with findings from a neoadjuvant trial of axitinib in localized renal cell carcinoma (16) . An ongoing study at the MD Anderson Cancer Center is comparing axitinib with ADT to axitinib alone before radical prostatectomy in a similar patient population (17) . Another placebo-controlled, randomized phase II study led by the Huntsman Cancer Institute is exploring pazopanib before radical prostatectomy, also in men with high-risk localized disease (18) . Notably, the proposed time frame for accrual to these studies drastically exceeds those for studies of novel endocrine therapies and other drugs with documented activity in advanced prostate cancer. If these studies face a similar fate as ours, a pooled analysis of the results may provide the highest yield of clinical and translational data. 
